Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group (NASDAQ: REPL) announced the grant of inducement equity awards to 53 newly hired non-executive employees. The compensation package includes:
- 98,450 non-qualified stock options at $7.49 per share (closing price on April 7, 2025)
- 155,875 restricted stock units (RSUs)
The stock options have a 10-year term with a 4-year vesting schedule: 25% vests after one year, followed by monthly installments over three years. RSUs vest in four annual installments starting May 15, 2026. These inducement awards, approved under Nasdaq Rule 5635(c)(4), align with the company's 2018 Equity Incentive Plan terms despite being granted outside it.
Replimune Group (NASDAQ: REPL) ha annunciato l'assegnazione di premi azionari di indennizzo a 53 nuovi dipendenti non esecutivi. Il pacchetto retributivo include:
- 98.450 opzioni su azioni non qualificate a 7,49 $ per azione (prezzo di chiusura del 7 aprile 2025)
- 155.875 unità azionarie vincolate (RSU)
Le opzioni su azioni hanno un termine di 10 anni con un programma di maturazione di 4 anni: il 25% matura dopo un anno, seguito da rate mensili per tre anni. Le RSU maturano in quattro rate annuali a partire dal 15 maggio 2026. Questi premi di indennizzo, approvati ai sensi della Regola 5635(c)(4) di Nasdaq, sono in linea con i termini del Piano di Incentivazione Azionaria del 2018 dell'azienda, nonostante siano stati concessi al di fuori di esso.
Replimune Group (NASDAQ: REPL) anunció la concesión de premios de acciones de inducción a 53 nuevos empleados no ejecutivos. El paquete de compensación incluye:
- 98,450 opciones sobre acciones no calificadas a 7.49 $ por acción (precio de cierre del 7 de abril de 2025)
- 155,875 unidades de acciones restringidas (RSUs)
Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición de 4 años: el 25% se adquiere después de un año, seguido de cuotas mensuales durante tres años. Las RSUs se adquieren en cuatro cuotas anuales a partir del 15 de mayo de 2026. Estos premios de inducción, aprobados bajo la Regla 5635(c)(4) de Nasdaq, están alineados con los términos del Plan de Incentivos de Capital de 2018 de la compañía, a pesar de ser otorgados fuera de este.
Replimune Group (NASDAQ: REPL)는 53명의 새로 고용된 비상임 직원에게 유인 주식 보상을 부여한다고 발표했습니다. 보상 패키지에는 다음이 포함됩니다:
- 98,450개의 비자격 주식 옵션, 주당 7.49 달러 (2025년 4월 7일 종가)
- 155,875개의 제한 주식 단위 (RSU)
주식 옵션은 10년 기간을 가지며 4년의 베스팅 일정이 있습니다: 1년 후 25%가 베스팅되고, 이후 3년 동안 매월 할부로 지급됩니다. RSU는 2026년 5월 15일부터 시작하여 4회의 연간 할부로 베스팅됩니다. 이러한 유인 보상은 Nasdaq 규칙 5635(c)(4) 아래에서 승인되었으며, 회사의 2018년 자본 인센티브 계획의 조건과 일치하지만, 그 외부에서 부여되었습니다.
Replimune Group (NASDAQ: REPL) a annoncé l'octroi de récompenses en actions d'incitation à 53 nouveaux employés non exécutifs. Le package de rémunération comprend :
- 98 450 options d'achat d'actions non qualifiées à 7,49 $ par action (prix de clôture du 7 avril 2025)
- 155 875 unités d'actions restreintes (RSUs)
Les options d'achat d'actions ont une durée de 10 ans avec un calendrier d'acquisition de 4 ans : 25 % s'acquièrent après un an, suivis de versements mensuels sur trois ans. Les RSUs s'acquièrent en quatre versements annuels à partir du 15 mai 2026. Ces récompenses d'incitation, approuvées en vertu de la règle 5635(c)(4) de Nasdaq, s'alignent sur les conditions du Plan d'Incentives en Actions de 2018 de l'entreprise, bien qu'elles aient été accordées en dehors de celui-ci.
Replimune Group (NASDAQ: REPL) gab die Gewährung von Anreiz-Aktienvergütungen an 53 neu eingestellte nicht-executive Mitarbeiter bekannt. Das Vergütungspaket umfasst:
- 98.450 nicht qualifizierte Aktienoptionen zu 7,49 $ pro Aktie (Schlusskurs am 7. April 2025)
- 155.875 eingeschränkte Aktieneinheiten (RSUs)
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem 4-jährigen Vesting-Zeitplan: 25% vesten nach einem Jahr, gefolgt von monatlichen Raten über drei Jahre. RSUs vesten in vier jährlichen Raten, beginnend am 15. Mai 2026. Diese Anreizvergaben, die gemäß der Nasdaq-Regel 5635(c)(4) genehmigt wurden, entsprechen den Bedingungen des Aktienoptionsplans von 2018 des Unternehmens, obwohl sie außerhalb dieses Plans gewährt wurden.
- Successful recruitment of 53 new employees indicates company expansion
- Structured equity compensation plan helps attract and retain talent
- Equity compensation grants will result in future shareholder dilution
WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 53 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 98,450 shares of the Company's common stock and restricted stock units representing an aggregate of 155,875 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under such plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
How many new employees received REPL stock inducement grants in April 2025?
What is the exercise price for REPL's inducement stock options granted on April 7, 2025?
What is the vesting schedule for REPL's inducement RSUs granted in April 2025?
How many REPL stock options and RSUs were granted in the April 2025 inducement awards?
